🔗 Share this article

Given that the US undertakes sweeping revisions to its vaccination schedules, one figure appears somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by casting doubt on Covid vaccinations throughout the pandemic and has concentrated on possible deaths after Covid immunization in her short tenure at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Vaccine Schedule

Health officials planned to reveal major changes to the childhood vaccine schedule recently, aligning the US with the Danish national calendar, according to reports – a major change that would place the US at odds with a large portion of the international standard with no evidence for benefit. This reveal has been postponed until the coming year.

Instead of the director of the vaccine center, Høeg is set to speak at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the division this calendar year.

Consolidating Power at the Regulatory Body

This interim role may indicate a strengthened alliance between the drug and biologics branches as Høeg and Prasad consolidate power at the agency – and it points to a greater focus upon rolling back long-standing vaccines at the FDA.

The new acting director has repeatedly called for halting some pediatric immunization guidelines in the US in order to be more in line with the Danish model, a nation with universal health coverage and a citizenry roughly the size of the state of Wisconsin.

In her initial statements, she has continued to focus on vaccines – typically the domain of Prasad, head of the FDA’s vaccine center – rather than drug regulation.

Questions Over Expertise

Dr. Høeg has little discernible track record in medication creation, regulation or management, which has been typical for previous leaders of the biologics center. She has served at the FDA as a key advisor to the commissioner and the vaccine center since earlier this year.

“She appears not to have the requisite experience” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in leading a major agency. She has no expertise in drug approvals.”

Former commissioners of the center would “grasp regulatory frameworks and the science of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Frankly, she lacks the kind of background that prior appointees who led the center have had.”

The drug center has an vast workload at the FDA, the former commissioner emphasized.

“Many people just pays attention on the novel medication approvals, but the generic program approves thousands of generic drugs. There’s a biologic copycat branch, over-the-counter program and more, and all of those need to be supervised,” she noted. “The thing you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a significant leadership component to the job, which oversees over 5,000 employees. “It’s a massive leadership role, if you execute it properly,” Woodcock concluded.

Official Statement and Controversial Programs

Regarding concerns about Høeg’s fitness for the role and whether this appointment signifies greater collaboration among FDA leaders on immunizations, a representative responded that the “concerns are based on flawed assumptions”.

“Her resume matches the responsibilities of her job,” the spokesperson said, citing the months Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s new expedited review system, a controversial one-day therapy clearance system that allegedly worried her predecessors. “How are these drugs being chosen for this fast-track system? Who takes the choices?” Dr. Howard questioned. “There’s a lot of confidentiality happening at the FDA right now.”

In general, he stated, “the Food and Drug Administration appears to be shifting towards more relaxed regulations of most medications, except for immunizations.”

Established History on Immunizations

Concerning vaccines, Dr. Høeg has a more documented, if concerning, track record, critics said. She published a research paper using unverified public submissions to estimate the frequency of myocarditis after Covid immunization. She advised the Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccinations are riskier than they are.

Part of her “desired changes” for the incoming administration included changing rules for novel immunizations and discontinuing “optional” vaccines, she said post-election on a podcast. At the FDA, Høeg has reportedly proposed excluding teenage boys from obtaining Covid vaccines.

“She’s an all-around true believer who commences with her beliefs and works backwards to fit the evidence in a very misleading, dishonest manner,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg became part of fellow contrarians, {like|